Nothing Special   »   [go: up one dir, main page]

BR112016010080A8 - compostos de pirazolopirimidina, composição farmacêutica e seu uso - Google Patents

compostos de pirazolopirimidina, composição farmacêutica e seu uso Download PDF

Info

Publication number
BR112016010080A8
BR112016010080A8 BR112016010080A BR112016010080A BR112016010080A8 BR 112016010080 A8 BR112016010080 A8 BR 112016010080A8 BR 112016010080 A BR112016010080 A BR 112016010080A BR 112016010080 A BR112016010080 A BR 112016010080A BR 112016010080 A8 BR112016010080 A8 BR 112016010080A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pyrazolopyrimidine compounds
relates
present
pyrazolopyrimidine
Prior art date
Application number
BR112016010080A
Other languages
English (en)
Other versions
BR112016010080B1 (pt
Inventor
Ng Grace
W Pauls Heinz
Kumar B Patel Narendra
Laufer Radoslaw
Li Sze-Wan
Liu Yong
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of BR112016010080A8 publication Critical patent/BR112016010080A8/pt
Publication of BR112016010080B1 publication Critical patent/BR112016010080B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção refere-se a um composto representado pela seguinte fórmula estrutural: (i); ou um sal farmaceuticamente aceitável do mesmo. a presente invenção também se refere a composições farmacêuticas e a métodos de utilização das mesmas.
BR112016010080-8A 2012-11-16 2014-11-14 compostos de pirazolopirimidina, composição farmacêutica e seu uso BR112016010080B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261727581P 2012-11-16 2012-11-16
US201361808152P 2013-04-03 2013-04-03
PCT/CA2013/000957 WO2014075168A1 (en) 2012-11-16 2013-11-15 Pyrazolopyrimidine compounds
CAPCT/CA2013/000957 2013-11-15
PCT/CA2014/051091 WO2015070349A1 (en) 2012-11-16 2014-11-14 Pyrazolopyrimidine compounds

Publications (2)

Publication Number Publication Date
BR112016010080A8 true BR112016010080A8 (pt) 2020-04-14
BR112016010080B1 BR112016010080B1 (pt) 2020-12-29

Family

ID=50730425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016010080-8A BR112016010080B1 (pt) 2012-11-16 2014-11-14 compostos de pirazolopirimidina, composição farmacêutica e seu uso

Country Status (24)

Country Link
US (9) US9573954B2 (pt)
EP (2) EP2920181B1 (pt)
JP (1) JP6377068B2 (pt)
CN (1) CN105793261B (pt)
AU (1) AU2013344716B2 (pt)
BR (1) BR112016010080B1 (pt)
CA (1) CA2889919C (pt)
CY (1) CY1120480T1 (pt)
DK (1) DK3068786T3 (pt)
ES (1) ES2686097T3 (pt)
HR (1) HRP20181041T1 (pt)
HU (1) HUE039351T2 (pt)
IL (1) IL245187B (pt)
LT (1) LT3068786T (pt)
ME (1) ME03093B (pt)
MX (1) MX2016006336A (pt)
NZ (1) NZ707432A (pt)
PL (1) PL3068786T3 (pt)
PT (1) PT3068786T (pt)
RS (1) RS57481B1 (pt)
SG (1) SG11201603102TA (pt)
SI (1) SI3068786T1 (pt)
TW (1) TWI679201B (pt)
WO (2) WO2014075168A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889919C (en) * 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
JP6095857B2 (ja) * 2013-11-15 2017-03-15 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
CN107073079A (zh) * 2014-09-08 2017-08-18 达纳－法伯癌症研究所公司 包括给予PPAR‑γ激动剂的治疗癌症的方法
EP3215509B1 (en) 2014-11-06 2020-02-26 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
EP3215510B1 (en) 2014-11-06 2023-06-07 Bial-R&D Investments, S.A. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
IL252053B2 (en) 2014-11-06 2024-04-01 Lysosomal Therapeutics Inc Converted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders
CN107949563B (zh) * 2015-06-24 2020-06-05 库洛维公司 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物
JP7046827B2 (ja) 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
CA3020287A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
FI3484888T5 (fi) * 2016-07-18 2024-02-26 Univ Health Network Ttk:n estäjän kiinteitä muotoja
CN117946115A (zh) 2017-07-28 2024-04-30 武田药品工业株式会社 Tyk2抑制剂与其用途
WO2019023786A1 (en) * 2017-08-01 2019-02-07 University Health Network COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE
TW202003520A (zh) * 2018-05-23 2020-01-16 加拿大健康網路大學 Ttk抑制之生物標記
MD20210033A2 (ro) 2018-10-30 2021-10-31 Kronos Bio, Inc. Compuşi, compoziţii şi metode pentru modularea activităţii CDK9
CN111377925B (zh) * 2018-12-28 2024-03-12 四川科伦博泰生物医药股份有限公司 嘌呤类衍生物、其制备方法及其在医药上的应用
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
CN113773324B (zh) * 2021-09-07 2022-07-26 武汉九州钰民医药科技有限公司 抗肿瘤药cfi-402257的合成制备工艺
CN116396298A (zh) * 2023-06-06 2023-07-07 四川维亚本苑生物科技有限公司 CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021556A (en) * 1972-06-08 1977-05-03 Icn Pharmaceuticals, Inc. Xanthine oxidase inhibitors
JPH04156453A (ja) 1990-10-19 1992-05-28 Konica Corp 新規な写真用カプラー
JPH04156452A (ja) 1990-10-19 1992-05-28 Konica Corp 新規な写真用カプラー
US6124289A (en) 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
WO2000059907A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
EA200200422A1 (ru) 1999-09-30 2002-10-31 Ньюроджен Корпорейшн НЕКОТОРЫЕ АЛКИЛЕНДИАМИНОЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]-1,5-ПИРИМИДИНЫ И ПИРАЗОЛО[1,5-а]-1,3,5-ТРИАЗИНЫ
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
JP2005525382A (ja) 2002-03-07 2005-08-25 スミスクライン ビーチャム コーポレーション ピラゾロピリミジンおよびピラゾロトリアジン誘導体ならびにそれを含む医薬組成物
CN100343255C (zh) 2002-04-23 2007-10-17 盐野义制药株式会社 吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
FR2842809A1 (fr) 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
AU2003265585B2 (en) 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
US7605155B2 (en) 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
CN1310918C (zh) 2002-09-04 2007-04-18 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ539165A (en) 2002-09-04 2008-03-28 Schering Corp Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
US7569571B2 (en) 2003-12-23 2009-08-04 Novartis Ag Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators
AR047969A1 (es) 2004-02-25 2006-03-15 Schering Corp Pirazolotriazinas como inhibidores de quinasa
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP1942900B1 (en) * 2005-10-06 2015-06-03 Merck Sharp & Dohme Corp. Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
AU2007316417B2 (en) 2006-11-06 2013-08-22 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
EP2178375B1 (en) * 2007-07-20 2014-09-24 Merck Sharp & Dohme Corp. Pyrazoloý1,5-a¨pyrimidine derivatives
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
GB0908957D0 (en) 2009-05-22 2009-07-01 Ucb Pharma Sa Therapeutic agents
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2525659B1 (en) 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
JP5824040B2 (ja) 2010-06-01 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピラジン
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
US20120149708A1 (en) 2010-06-17 2012-06-14 George Mason University Modulators of viral transcription, and methods and compositions therewith
EP3012258B1 (en) 2010-06-24 2018-09-19 Gilead Sciences, Inc. Pharmaceutical composition comprising a pyrazolo[1,5-a]pyrimidine derivative as an antiviral agent
EP2402337A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651945A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651950A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012100229A2 (en) 2011-01-21 2012-07-26 The General Hospital Corporation Compositions and methods for cardiovascular disease
US20140255392A1 (en) 2011-04-06 2014-09-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
ES2576484T3 (es) 2011-10-20 2016-07-07 Glaxosmithkline Llc Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds

Also Published As

Publication number Publication date
US20170217966A1 (en) 2017-08-03
US10106545B2 (en) 2018-10-23
EP3068786A1 (en) 2016-09-21
TWI679201B (zh) 2019-12-11
US20150299203A1 (en) 2015-10-22
DK3068786T3 (en) 2018-07-16
US10570143B2 (en) 2020-02-25
US20160137651A1 (en) 2016-05-19
CA2889919C (en) 2021-08-17
CN105793261A (zh) 2016-07-20
EP2920181A4 (en) 2016-07-27
EP3068786B1 (en) 2018-06-06
SI3068786T1 (sl) 2018-09-28
US9573954B2 (en) 2017-02-21
MX2016006336A (es) 2016-09-06
WO2014075168A1 (en) 2014-05-22
AU2013344716B2 (en) 2018-03-01
HUE039351T2 (hu) 2018-12-28
US20190040074A1 (en) 2019-02-07
US20220204511A1 (en) 2022-06-30
JP6377068B2 (ja) 2018-08-22
LT3068786T (lt) 2018-08-27
CA2889919A1 (en) 2014-05-22
EP3068786A4 (en) 2017-04-12
EP2920181A1 (en) 2015-09-23
US9657025B2 (en) 2017-05-23
PT3068786T (pt) 2018-07-26
IL245187A0 (en) 2016-06-30
ME03093B (me) 2019-01-20
US10167289B2 (en) 2019-01-01
NZ707432A (en) 2020-01-31
WO2015070349A1 (en) 2015-05-21
RS57481B1 (sr) 2018-10-31
US20210009595A1 (en) 2021-01-14
SG11201603102TA (en) 2016-05-30
JP2015537008A (ja) 2015-12-24
IL245187B (en) 2019-12-31
AU2013344716A1 (en) 2015-05-14
EP2920181B1 (en) 2019-01-09
TW201605860A (zh) 2016-02-16
CY1120480T1 (el) 2019-07-10
US20190322669A1 (en) 2019-10-24
US20170320881A1 (en) 2017-11-09
HRP20181041T1 (hr) 2018-09-21
US20240287077A1 (en) 2024-08-29
CN105793261B (zh) 2018-11-30
PL3068786T3 (pl) 2018-10-31
ES2686097T3 (es) 2018-10-16
BR112016010080B1 (pt) 2020-12-29

Similar Documents

Publication Publication Date Title
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
EA201591195A1 (ru) Новые хинолоновые производные
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201600366A1 (ru) Производные бензимидазол-пролина
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
IN2014MN02106A (pt)
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
BR112015004523A2 (pt) compostos de tetraciclina
EA201600434A1 (ru) Применение производных бензимидазолпролина
BR112012031340A2 (pt) derivados de cianoquinolina
EA201501163A1 (ru) Модуляторы рецептора cxcr7
EA201600394A1 (ru) Трициклические соединения пиперидина
EA201490573A1 (ru) Соединение бензотиазолона
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
IN2015DN00085A (pt)
WO2013106756A3 (en) Antimicrobial agents
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
BR112015006243A2 (pt) agentes antibacterianos de fenicol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/11/2014, OBSERVADAS AS CONDICOES LEGAIS.